Reported Earlier, Vaxcyte Prices $1.3B Public Offering Of 10,194,175 Common Shares And Pre-Funded Warrants At $103/Share
Reported Earlier, Vaxcyte Prices $1.3B Public Offering Of 10,194,175 Common Shares And Pre-Funded Warrants At $103/Share
Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
vaxcyte正在出售10,194,175股普通股和提前融资权证，以购买2,427,184股普通股。普通股的发行价为每股103.00美元，提前融资权证的发行价为每份提前融资权证102.999美元。提前融资权证的行权价为每股0.001美元。预计vaxcyte从本次发行中的总收益约为13亿美元，未计算承销折扣、佣金和其他发行费用，并且未包括任何提前融资权证的行使。本次发行的所有普通股和提前融资权证的出售将由vaxcyte提供。